Go to the list of all blogs
Harry Richardson's Avatar
published in Blogs
Aug 05, 2026
Element Solutions (ESI) Shares Decline -8% as Solstice Acquisition Premium Erodes

Element Solutions (ESI) Shares Decline -8% as Solstice Acquisition Premium Erodes

Key Takeaways

  • Element Solutions shares have declined approximately 8% over the past 30 days as the initial merger premium from the Solstice Advanced Materials acquisition announcement continues to erode.
  • The $14.5 billion cash-and-stock buyout, announced July 6, valued ESI at roughly $50.10 per share — a level the stock has since drifted significantly below amid shareholder dissatisfaction on both sides.
  • Mizuho downgraded ESI to Neutral from Outperform following the deal announcement, lowering its price target from $54 to $45 and citing a low probability of a competing bid.
  • Quarterly performance reflects a broader pullback: ESI shares are down more than 11% over the past three months, pressured by deal-related uncertainty and softening sentiment in specialty chemicals.
  • Analyst consensus remains a moderate "Buy," though the average price target has compressed toward $43 as firms recalibrate around the deal's implied valuation mechanics.

ESI's Current Market Position

Element Solutions Inc. (ESI) trades near $38.89 as of early August 2026, marking a notable retreat from the mid-$40s range the stock occupied before the Solstice Advanced Materials acquisition was unveiled. The specialty chemicals company, which generates over 70% of its revenue from electronics-facing applications, has seen its share price become increasingly tethered to SOLS — the acquiring entity — since the deal's cash-and-stock structure ties roughly 80% of the transaction value to Solstice equity. Broader sector headwinds, including cooling AI-linked sentiment and macroeconomic uncertainty, have compounded the post-announcement drift. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Understanding Element Solutions' Business and Competitive Position

Element Solutions is a global specialty chemicals technology company serving two primary segments: Electronics (MacDermid Alpha Electronics Solutions) and Industrial & Specialty (Element Specialties). The Electronics segment — contributing roughly 70% of total revenue — supplies mission-critical consumable chemistries for semiconductor packaging, printed circuit board fabrication, circuit assembly, and thermal management. Key end markets include mobile communications, computing, automotive electronics, and aerospace. The Industrial & Specialty segment provides electroless nickel plating, functional conversion coatings, and offshore energy fluids. With approximately 5,200 employees, operations across 18 countries, and an asset-light consumables business model, ESI has positioned itself at the intersection of AI data center buildout, advanced semiconductor packaging, and automotive electrification — secular trends that have attracted significant investor attention. The company completed strategic acquisitions of EFC Gases & Advanced Materials (January 2026) and Micromax (February 2026), further deepening its electronics portfolio.

Key Recent Events Shaping ESI's Path

The dominant development over the last 30 days has been the July 6 announcement that Solstice Advanced Materials — the specialty materials company spun out of Honeywell in October 2025 — will acquire Element Solutions in a transaction valued at approximately $14.5 billion, including assumed net debt. Under the terms, ESI shareholders receive $10.00 in cash plus 0.500 shares of Solstice common stock per ESI share, representing implied consideration of roughly $50.10 — a 15% premium to the pre-announcement closing price.

Rather than sustaining that premium, ESI shares have retreated significantly since the announcement. Multiple factors are at play. Mizuho analyst John Roberts downgraded ESI to Neutral, noting that both sets of shareholders were "less than pleased." ESI investors reportedly hoped for a pure-play electronics chemical company, while Solstice shareholders favored a different structure. Several shareholder rights law firms also initiated investigations into the fairness of the transaction process. S&P Global Ratings placed both companies on CreditWatch Negative, citing expected leverage well above 3.0x at close. The cash-and-stock nature of the deal means ESI's trading price now largely reflects the market's reassessment of Solstice's standalone value, which itself declined roughly 21% in the aftermath.

Prior to the deal announcement, ESI was riding positive momentum from a strong Q1 2026 earnings report in late April, which delivered EPS of $0.41 on revenue of $840 million — both comfortably above consensus. Analysts at BofA Securities, Truist, and BMO Capital all raised price targets following the beat, citing robust organic growth in the Electronics segment tied to AI and data center demand.

Looking Ahead: Outlook for 2026 and Beyond

The primary variable shaping ESI's trajectory through year-end 2026 and into 2027 is the progress and ultimate closing of the Solstice acquisition, expected in the first half of 2027. Key milestones include shareholder votes from both companies, regulatory approvals, and Solstice's permanent debt financing to replace the $4.7 billion bridge commitment from Goldman Sachs. The implied deal value will continue to fluctuate with Solstice's share price, making ESI effectively a derivative on SOLS in the near term.

Beyond the deal, investors should monitor Element Solutions' Q2 2026 earnings, which will provide a read on whether the organic growth momentum observed in Q1 — particularly the 15% organic expansion in Electronics — is sustainable. Macro risks include potential softening in semiconductor capital expenditure cycles, trade policy shifts affecting electronics supply chains, and metals price volatility. On the positive side, the structural tailwinds of AI infrastructure investment, data center expansion, and advanced packaging adoption remain intact. The $180 million in projected net cost synergies and the combined company's target of mid-to-high single-digit revenue growth provide a credible long-term framework, though execution risk on an integration of this scale — for a company only recently independent itself — is a legitimate concern flagged by credit rating agencies. From what I see, monitoring these factors closely will be essential as the situation evolves.

Exploring AI-Driven Tools for Analysis

In navigating situations like this where deal mechanics and external factors create layered uncertainty, I find it helpful to incorporate quantitative perspectives alongside traditional research. Tickeron's AI Trading Bots offer a way to examine pattern-based signals and backtested strategies across various timeframes, which can add discipline when evaluating how stocks like ESI might respond to ongoing developments. This approach has become a regular part of my process for cross-checking market dynamics without replacing fundamental analysis.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ESI

ESI's RSI Indicator ascends from oversold territory

The RSI Indicator for ESI moved out of oversold territory on July 30, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 22 similar instances when the indicator left oversold territory. In of the 22 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 03, 2026. You may want to consider a long position or call options on ESI as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ESI just turned positive on August 04, 2026. Looking at past instances where ESI's MACD turned positive, the stock continued to rise in of 55 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ESI advanced for three days, in of 289 cases, the price rose further within the following month. The odds of a continued upward trend are .

ESI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

ESI moved below its 50-day moving average on July 06, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ESI crossed bearishly below the 50-day moving average on July 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ESI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ESI entered a downward trend on August 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock slightly better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.369) is normal, around the industry mean (7.140). P/E Ratio (52.554) is within average values for comparable stocks, (33.231). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (72.246). Dividend Yield (0.008) settles around the average of (0.020) among similar stocks. P/S Ratio (3.000) is also within normal values, averaging (97.087).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ESI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are DuPont de Nemours (NYSE:DD), Chemours Company (The) (NYSE:CC).

Industry description

The specialty chemicals sector includes companies that produce chemicals and industrial gases, which are of relatively high-value, often made to customer specifications. Examples of specialty chemicals are electronic chemicals, industrial gases, coatings, adhesives and sealants, industrial and institutional cleaning chemicals. The products are often valued on the basis of their purposes/performances rather than for their composition. Linde Plc, Ecolab Inc., Air Products and Chemicals, Inc., and Dow, Inc. are some of the largest companies making specialty chemicals.

Market Cap

The average market capitalization across the Chemicals: Specialty Industry is 11.99B. The market cap for tickers in the group ranges from 47 to 223.41B. LIN holds the highest valuation in this group at 223.41B. The lowest valued company is GTBT at 47.

High and low price notable news

The average weekly price growth across all stocks in the Chemicals: Specialty Industry was 5%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was 10%. LWLG experienced the highest price growth at 38%, while CBT experienced the biggest fall at -10%.

Volume

The average weekly volume growth across all stocks in the Chemicals: Specialty Industry was -10%. For the same stocks of the Industry, the average monthly volume growth was -2% and the average quarterly volume growth was -11%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 53
P/E Growth Rating: 56
Price Growth Rating: 53
SMR Rating: 78
Profit Risk Rating: 82
Seasonality Score: -20 (-100 ... +100)
View a ticker or compare two or three
ESI
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a provider of technology chemical products and technical services

Industry ChemicalsSpecialty

Profile
Details
Industry
Chemicals Specialty
Address
500 East Broward Boulevard
Phone
+1 561 207-9600
Employees
5300
Web
https://www.elementsolutionsinc.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.